Pemetrexed plus platinum outperforms other platinum-based adjuvant chemotherapy regimens for resected stage II-IIIA lung adenocarcinoma: an open-label, historical-control study.

OS analysis of IMpower 010 indicates a positive trend favouring atezolizumab after adjuvant chemotherapy in PD-L1 positive subgroup analyses, primarily driven by the PD-L1 tumor cell ≥50% stage II–IIIA subgroup ( 18 ).

also in 11,005 other papers

This suggests that EGFR mutation status primarily predicts benefit from EGFR-TKI therapy, while its prognostic role in the natural disease course or in platinum-based adjuvant chemotherapy may not be significant.

also in 2,774 other papers